Akero Therapeutics | Efruxifermin for NASH

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Nov 2022 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrates improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph The Liver Meeting 2022 (AASLD)

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Erik Tillman Keystone Symposium on Adipose Tissue and Metabolic Health

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Erik J Tillman, Reshma Shringarpure, Guy Neff, Rashmee Patil, Bradley Freilich, Cynthia Behling, Erica Fong, Brittany de Temple, Kitty Yale, Stephen A Harrison, Tim Rolph The International Liver Congress™ 2022 (EASL)

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

Erik J Tillman, Louben Dorval, Reshma Shringarpure, Erica Fong, Brittany de Temple, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies